Argenx's study flop in Sjögren's overshadows a win in celiac disease

Phase 3negativeNegative

AI Analysis

Summary

Argenx reported a Phase 3 trial failure in Sjögren's disease while achieving a success in celiac disease, resulting in a significant share price decline. The company is shuttering the Sjögren's program due to the trial setback.

Clinical Trial Data

Phase

Primary Endpoint

Not Met

Outcome Details

Phase 3 trial in Sjögren's being shuttered

Importance:7/10

Sentiment:

-0.70

autoimmune diseasetrial failurepipeline setbackmixed results

Related Companies

$ARGX

Read the original article

Published by Endpoints News on October 8, 2026 11:00 AM

Read Original